Anti-PD-L1 intervention prolonged animals’ life expectancy to 83.0 ± 5.7 days (p = 0.001 when compared with appropriate control subgroup) in luminal primary NMIBC subgroup, to 74.5 ± 4.0 days (p = 0.001 when compared with non-interventional subgroup) in the basal relapsed bladder cancer subgroup, to 67.8 ± 3.5 days (p = 0.03 when compared with non-interventional subgroup) in the basal primarily bladder cancer subgroup, and to 77.8 ± 5.3 days (p = 0.002 when compared with non-interventional subgroup) in the subgroup of animals that carried relapsed luminal NMIBC PDX. This evidence concerns the gene CD274 and urinary bladder cancer.